CD4 and melanoma: This result is consistent with another study that showed that CD4-positive T-cell responses were more strongly induced than CD8-positive T-cell responses when mRNA vaccines targeting both HLA class I-restricted neoantigens and HLA class II-restricted neoantigens were administered in melanoma patients [11].